Prevalence of colonisation and genotypic characterisation of Pneumocystis jirovecii among cystic fibrosis patients in Spain  by Respaldiza, N. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01276.x
Prevalence of colonisation and genotypic characterisation of Pneumocystis
jirovecii among cystic ﬁbrosis patients in Spain
N. Respaldiza, M. A. Montes-Cano, F. J. Dapena, C. de la Horra, I. Mateos, F. J. Medrano, E. Calderon
and J. M. Varela
Department of Internal Medicine and Cystic Fibrosis Unit, Virgen del Rocı´o University Hospital,
Seville, Spain
ABSTRACT
Pneumocystis jirovecii colonisation may occur among cystic ﬁbrosis (CF) patients because of their
underlying pulmonary disease. A wide epidemiological analysis was performed among CF patients
from Spain to assess the prevalence of P. jirovecii colonisation and the distribution of different genotypes.
P. jirovecii was identiﬁed by nested PCR targeting the mitochondrial large-subunit rRNA gene from
sputum samples or oropharyngeal washes. The genotype was determined by direct sequencing. The
prevalence of P. jirovecii colonisation among 88 consecutive CF patients was 21.5%. The polymorphisms
identiﬁed were 85C ⁄ 248C (45.4%), 85T ⁄ 248C (27.2%) and 85A ⁄ 248C (18.1%); in one case, a mix of
genotypes was found. Colonisation was more frequent in subjects aged < 18 years (25.5% vs. 15.1%).
Among the patients studied, 20.8% received treatment with azithromycin; all of these patients were
colonised with P. jirovecii, but none developed Pneumocystis pneumonia (PcP) during a 1-year follow-up
period. Concordance in the colonisation status of siblings suggested a common source of infection or
person-to-person transmission.
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INTRODUCTION
Cystic ﬁbrosis (CF) is the most common serious
hereditary disorder in the Caucasian population.
Several organs are affected in this disorder, with
chronic bronchopulmonary damage being the
most serious clinical problem [1]. One important
factor that contributes to these lesions is the
presence in the respiratory tract of CF patients of
opportunistic pathogens, such as Pseudomonas
aeruginosa, Staphylococcus aureus, non-typeable
Haemophilus inﬂuenzae and Burkholderia cepacia
[2]. Chemoprophylaxis for these infections, and
lung transplantation, have improved the progno-
sis and survival of patients with CF [3].
Pneumocystis jirovecii, known previously as
Pneumocystis carinii f. sp. hominis [4,5], is an
atypical opportunistic fungus with lung tropism
and worldwide distribution that causes pneu-
monia in immunosuppressed individuals. During
the last 10 years, the incidence of Pneumocystis
pneumonia (PcP) has decreased in AIDS patients
in developed countries. However, an increasing
number of PcP cases has been reported in human
immunodeﬁciency virus-negative immunosup-
pressed patients, such as those with malignancy,
transplants or connective tissue diseases [6,7].
The introduction of new techniques for Pneu-
mocystis diagnosis, such as immunoﬂuorescence
with monoclonal antibodies and PCR, has im-
proved the detection of infections from samples
obtained by non-invasive methods, and from
samples with a low pathogen load. With use of
these more sensitive methods, Pneumocystis car-
riage has been demonstrated in 10–40% of
immunocompetent patients with various chronic
lung diseases [2,8]. In addition, serological studies
conducted in Spain have shown that healthy, non-
immunocompromised adults frequently have
serum antibodies to Pneumocystis [9], and that
the primary contact usually occurs at an early age
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[10]. However, the basic epidemiology of human
P. jirovecii infection and the host–microorganism
relationship remain poorly understood.
A previous study of CF patients from Spain did
not identify the pathogen by conventional stain-
ing methods [11]. P. jirovecii has been identiﬁed
by nested PCR in the respiratory tract of CF
patients [2,12,13], but much remains unknown
with respect to the molecular epidemiology of
P. jirovecii infection among CF patients. The aim
of the present study was to perform a wide
epidemiological analysis in order to provide
information regarding the prevalence of colonisa-
tion and distribution of P. jirovecii genotypes
among CF patients from Spain.
MATERIALS AND METHODS
Patients
Consecutive patients with CF (n = 88) who attended a spe-
cialised unit between May 2001 and July 2002 were included in
the study. The informed consent of patients or their guardians
was obtained in all cases. The Ethics Committee on Clinical
Research of the Virgen del Rocio University Hospital approved
the study. Patients were followed for 1 year. Every 6 months,
all patients underwent a clinical and biological examination
with the aid of a standardised questionnaire. Oropharyngeal
washes and ⁄ or sputum samples were collected from the
patients at baseline for P. jirovecii identiﬁcation.
Detection of P. jirovecii
DNA from P. jiroveciiwas extracted using a QIAmp DNAMini
Kit (Qiagen, Hilden, Germany) with proteinase K digestion at
56C, following the manufacturer’s instructions. A two-step
PCR for detection of the mitochondrial large-subunit rRNA
(mt LSU rRNA) gene was used as described previously [14].
Brieﬂy, the external primers pAZ102-E (5¢-GATGGCT-
GTTTCCAAGCCCA-3¢) and pAZ102-H (5¢-GTGTACGTTGC-
AAAGTACTC-3¢) yielded a 346-bp fragment. The nested
primers pAZ102-X (5¢-GTGAAATACAAATCGGACTAGG-3¢)
and pAZ102-Y (5¢-TCACTTAATATTAATTGGGGAGC-3¢)
yielded a 260-bp product. Both rounds of PCR comprised
40 ampliﬁcation cycles. Amplicons were analysed by electro-
phoresis on an agarose 1.5% w ⁄v gel containing ethidium
bromide, with subsequent UV visualisation. To prevent cross-
contamination, separate DNA extraction, pre-ampliﬁcation,
ampliﬁcation and detection areas were used. Negative ampli-
ﬁcation controls were used. All experiments were performed
at least twice.
Case deﬁnition
A P. jirovecii-colonised patient was deﬁned as an individual,
without symptoms or thorax radiography signs of PcP, from
whom a respiratory specimen was obtained that contained
detectable P. jirovecii DNA by nested PCR in two independent
analyses. Other individuals were considered to be Pneumocys-
tis-negative.
Genotypic characterisation at the mt LSU rRNA gene of
P. jirovecii
All samples positive by nested PCR were sequenced, and
polymorphisms at nucleotide positions 85 and 248 were
detected. The PCR products were puriﬁed using Sephacryl S-
400 columns (Amersham Pharmacia Biotech, Upsala, Sweden)
and re-ampliﬁed using 4 lL of the ABI Prism dRhodamine
Terminator Cycle Sequencing Ready Reaction Kit (PE Applied
Biosystems, Foster City, CA, USA) with 5 lL of PCR product
and 3 pmol of primer. Extension products were puriﬁed by
ethanol precipitation. Sample pellets were resuspended in
12.5 lL of template suspension reagent and then heated at
95C for 3 min. Analysis was performed on an ABI Prism 310
Sequencer (PE Applied Biosystems) according to the manu-
facturer’s instructions. The DNA sequences obtained were
analysed using Sequence Navigator v. 1.0.1 (PE Applied
Biosystems).
Statistical analysis
Chi-square tests with Yates’s correction or Fisher’s exact test
were used for assessing differences between proportions, with
p < 0.05 considered to be signiﬁcant. Statistical analyses were
performed using SPSS v. 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
The study included 88 patients (41 males, 47
females; median age 15.8 years, range 1–35 years)
from whom 54 sputum samples and 34 oropha-
ryngeal washes were collected. To prevent
underlying bacterial infections, 24 patients were
receiving azithromycin, and two were receiving
prophylaxis with co-trimoxazole, including one
who was receiving both drugs. The study inclu-
ded eight pairs of brothers.
Prevalence and molecular epidemiology of
P. jirovecii
P. jirovecii colonisation was detected in 19 (21.6%)
CF patients. Eleven of these positive samples
yielded typing results for positions 85 and 248 of
the mt LSU rRNA gene. As shown in Table 1,
only three genetic polymorphisms were found
Table 1. Pneumocystis jirovecii mt LSU rRNA genotypes
found in Spanish patients with cystic ﬁbrosis
Genotype
Nucleotide
position/identity n %
1 85C ⁄ 248C 5 45.4
2 85A ⁄ 248C 2 18.2
3 85T ⁄ 248C 3 27.3
Mixed 85C ⁄ 248C
85T ⁄ 248C
1 9.1
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among the CF patients, with a mix of two
genotypes in one patient. Among the 88 patients,
14 of 55 aged 1–18 years were positive for P.
jirovecii colonisation, compared with ﬁve of 33
patients aged > 18 years (25.5% vs. 15.1%; p not
signiﬁcant).
P. jirovecii colonisation was detected in ﬁve
(20.8%) of 24 patients treated with azithro-
mycin. Among treated patients aged < 18 years,
two (22.2%) of nine patients were colonised,
compared with three (20%) of 15 adults.
Interestingly, none developed PcP during the
following period. There was complete concor-
dance between the sibling groups, in that six
were negative for P. jirovecii colonisation and
two were positive.
DISCUSSION
P. jirovecii colonisation was detected in 21.6% of
CF patients from Spain, compared with 7.4% in
the only previous similar study, which was
performed in German CF patients [2]. Similarly,
P. jirovecii was detected by nested PCR in 40.5%
of Spanish patients with chronic bronchitis [15],
compared with 19% of patients from Germany
with primary pulmonary disorders [16]. These
differences in prevalence among patients with
similar pathologies could be explained by a
variable geographical distribution of P. jirovecii.
Among the four mt LSU rRNA region geno-
types described previously in the Spanish popu-
lation [14], only three were found among the CF
patients in the present study. Genotype 85C ⁄ 248C
was the most prevalent, and the genotype distri-
bution among CF patients was similar to that
described in the Spanish population as a whole,
including patients with other chronic pulmonary
diseases [14]. Failure to obtain sequence data
could be related to the relatively small numbers of
P. jirovecii organisms present in colonised patients
[15,17].
Previous seroepidemiological studies per-
formed in this region have demonstrated a high
seroprevalence of Pneumocystis infection at an
early age [10]. In the present study, there was a
higher rate of P. jirovecii colonisation in younger
patients, which supports the hypothesis that P.
jirovecii is commonly acquired during early child-
hood [18]. The differences were not statistically
signiﬁcant, probably because of the low numbers
of patients included in the analysis.
There is little information available regarding
the reservoirs and infection sources of P. jirovecii
infection in humans. Airborne transmission of
Pneumocystis has been demonstrated in animal
models [19], and P. jirovecii has been identiﬁed in
air spores from both rural and hospital environ-
ments, suggesting the possibility of airborne
transmission [3]. This hypothesis is supported
by reports of case clusters of PcP among immuno-
suppressed patients, and transmission of Pneumo-
cystis from immunosuppressed patients to
immunocompetent healthcare workers [20,21].
The concordant results obtained in the present
study for CF siblings suggest the possibility of a
common source of infection or person-to-person
transmission.
Co-trimoxazole is a potent broad-spectrum
antibacterial agent, and is also the most effective
agent for prophylaxis of PcP. Chemoprophylaxis
with co-trimoxazole is common among immuno-
suppressed patients in order to prevent infec-
tions, including those caused by P. jirovecii [22].
Mutations in the dihydropteroate synthetase
gene have been associated with resistance fol-
lowing treatment with sulphonamides, and it
has been suggested that resistance may spread
subsequently into the general population [5].
Furthermore, resistance to co-trimoxazole has
been described in 25% of chronic bronchial
disease patients and in 33% of PcP-AIDS
patients in this population [15]. Among the CF
patients in the present study who received co-
trimoxazole prophylaxis, none were colonised
by P. jirovecii. A further 24 patients were treated
with azithromycin, which is used in CF treat-
ment for its anti-inﬂammatory and antibacterial
properties [23]. Previous studies have shown
that azithromycin is also effective for PcP
prophylaxis [24,25], but P. jirovecii was detected
in ﬁve (20.8%) of 24 patients treated with
azithromycin in the present study, although
none developed PcP during the course of the
following year.
In summary, this study describes, for the ﬁrst
time, the molecular epidemiology of P. jirovecii
infection in a cohort of CF patients. A high
prevalence of P. jirovecii colonisation was found
in Spanish CF patients, with a predominance of
genotypes 1 and 3. Further investigations will be
needed to elucidate the role of P. jirovecii coloni-
sation in the natural history of patients with
underlying lung disorders.
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